DUBLIN--(BUSINESS WIRE)--The "Global Epidermolysis Bullosa Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The epidermolysis bullosa therapeutics market will register a CAGR of almost 5% by 2023.
Despite the significant research activities undertaken over the past several decades, a promising treatment with very few side effects is not yet developed for the treatment of epidermolysis bullosa.
Hence, various government and private organizations are releasing funds to advance the research on the development of promising therapeutics that can demonstrate better safety and efficacy than the available medications for the treatment of epidermolysis bullosa.
The funding for the research on epidermolysis bullosa in Europe is also increasing. Such funding and financial supports are helpful for the development of novel therapeutic drugs for the treatment of epidermolysis bullosa.
Rising awareness about epidermolysis bullosa
Epidermolysis bullosa is a group of inherited diseases in which the skin becomes very brittle and forms acute blisters after a minor injury or gentle friction. Therefore, to avoid the delay in the diagnosis and the unawareness of the treatment options, several government and non-government organizations are conducting various awareness programs.
Lack of approved therapeutics
The unavailability of approved therapeutics for the treatment of epidermolysis bullosa is expected to hamper the growth of the epidermolysis bullosa therapeutics market over the forecast period.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.
Key Players
- Amryt Pharma
- Fresenius
- Johnson & Johnson
- Novartis
- Pfizer
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Comparison by product
- Antibiotics - Market size and forecast 2018-2023
- Analgesics - Market size and forecast 2018-2023
- Other therapeutics - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DRIVERS AND CHALLENGES
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 12: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amryt Pharma
- Fresenius
- Johnson & Johnson
- Novartis
- Pfizer
For more information about this report visit https://www.researchandmarkets.com/research/4fr6lq/global?w=4
